The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 5, 2006, Pages 1928-1937

  Dell, Susanne ^b   Peters, Swaantje ^b   Müther, Philipp ^b   Kociok, Norbert ^b   Joussen, Antonia M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTIBODY; CD31 ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 6,7 DIMETHOXY 3 PHENYLQUINOXALINE; 6,7-DIMETHOXY-3-PHENYLQUINOXALINE; AGPT PROTEIN, MOUSE; ANDROSTANE DERIVATIVE; CHROMONE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TYRPHOSTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSMOTIC PUMP; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CORNEA; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CHROMONES; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MICE; MICE, INBRED C57BL; MORPHOLINES; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TYRPHOSTINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33744751811     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1071     Document Type: Article

References (58)

1. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathog Inhib Cornea. 1987;6:250-257.
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
3. Primbs GB, Casey R, Wamser K, Snyder WJ, Crean DH. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers. 1998;29:832-838.
4. Huang AJ, Watson, Hernandez E, Tseng SC. Photothrombosis of corneal neovascularization by intravenous rose bengal and argon laser irradiation. Arch Ophthalmol. 1988;106:680-685.
5. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
6. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for VEGF in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
7. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
8. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
9. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci. 2003;44:117-123.
10. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15:205-213.
11. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004;15:215-228.
12. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242-245.
13. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholts C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126:3047-3055.
14. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543-554.
15. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
16. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. EMBO J. 2001;15:1239-1241.
17. Affleck DG, Bull DA, Bailey SH, et al. PDGF(BB) increases myocardial production of VEGF: shift in VEGF mRNA splice variants after direct injection of bFGF, PDGF(BB), and PDGF(AB). J Surg Res. 2002;107:203-209.
18. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
19. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. VEGF expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
20. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
21. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
22. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev. 2004;15:229-235.
23. Kovalenko M, Rönnstrand L, Heldin C-H, et al. Phosphorylation site-specific inhibition of platelet-derived growth Factor β-Receptor autophosphorylation by the receptor blocking tyrphostin AG 1296. Biochemistry. 1997;36:6260-6269.
24. Cross MJ, Stewart A, Hodgkin MN, Kerr DJ, Wakelam MJO. Wort-mannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. J Biol Chem. 1995;270:25352-25355.
25. Vlahos CJ, Matter WF, Brown RF, et al. Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3 kinase. J Immunol. 1995;1:54:2413-2422.
26. Proia AD, Chandler DB, Haynes WL, et al. Quantitation of corneal neovascularization using computerized image analysis. Lab Invest. 1988;58:473-479.
27. Benjamin LE, Itzhak H, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591-1598.
28. Darland DC, D'Amore P. Blood vessel maturation: vascular development comes of age. J Clin Invest. 1999;103:157-158.
29. Cursiefen C, Hofmann-Rummelt C, Küchle M, Schlötzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106.
30. McCracken JS, Burger PC, Klintworth GK. Morphologic observations on experimental corneal vascularization in the rat. Lab Invest. 1979;41:519-530.
31. Ashton N, Oliveira F. Nomenclature of pericytes: intramural and extramural. Br J Ophthalmol. 1966;50:119-123.
32. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol Vis Sci. 1996;37:1625-1632.
33. Burger PC, Chandler DB, Klintworth GK. Experimental corneal neovascularization: biomicroscopic, angiographic, and morphologic correlation. Cornea 1985-86;4:35-41.
34. Burger PC, Chandler DB, Klintworth GK. Corneal neovascularization as studied by scanning electron microscopy of vascular casts. Lab Invest. 1983;48:169-180.
35. Moromizato Y, Stechschulte S, Miyamoto K, et al. CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. Am J Pathol. 2000;157:1277-1281.
36. Totani L, Cumashi A, Piccoli A, Lorenzet R. Polymorphonuclear leukocytes induce PDGF release from IL-1β-treated endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1534-1540.
37. Cao R, Brakenhielm E, Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 2002;16:1575-1583.
38. Jain RK, Munn LL. Leaky vessels? - call Ang1! Nat Med. 2000;6:131-132.
39. Ambati BK, Joussen AM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002;120:1063-1068.
40. Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003;44:590-593.
41. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
42. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Cin Invest. 2003;111:1287-1295.
43. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 2000;6:1102-1103.
44. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol. 2000;24:75-78.
45. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000;102:898-901.
46. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211-220.
47. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature (London). 2000;407:242-248.
48. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286:2511-2514.
49. Distler JHW, Hirth, A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149-161.
50. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGFdependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA. 2002;99:11205-11210.
51. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240.
52. Reinmuth N, Liu W, Jung YD, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001;15:1239-1241.
53. Affleck DG, Bull DA, Bailey SH, et al. PDGF(BB) increases myocardial production of VEGF: shift in VEGF mRNA splice variants after direct injection of bFGF, PDGF(BB), and PDGF(AB). J Surg Res. 2002;107:203-209.
54. Nishishita T, Lin PC. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem. 2004;15:91:584-593.
55. Dolloff NG, Shulby SS, Nelson AV, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 2005;24:6848-6854.
56. Gao Z, Sasoaka T, Fujimori T, et al. Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem. 2005;280:9375-9389.
57. Walker TR, Moore SM, Lawson MF, Panettieri RA Jr, Chilvers ER. Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role in mediating airway smooth muscle proliferation. Mol Pharmacol. 1998;54:1007-1015.
58. Chadhary LR, Hrsuka, KA. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem. 2001;81:304-311.